What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Surgery
- Myocardial infarction
His primary areas of study are Internal medicine, Cardiology, Surgery, Myocardial infarction and Endocrinology.
His Internal medicine study frequently draws connections to other fields, such as Gastroenterology.
His Cardiology study which covers Hazard ratio that intersects with Rivaroxaban.
His Myocardial infarction study integrates concerns from other disciplines, such as Candesartan and Placebo.
His Stroke study combines topics from a wide range of disciplines, such as Anesthesia, Dabigatran, Atrial fibrillation, Warfarin and Apixaban.
In his research, Vitamin K antagonist is intimately related to Edoxaban, which falls under the overarching field of Apixaban.
His most cited work include:
- Dabigatran versus warfarin in patients with atrial fibrillation (7970 citations)
- Apixaban versus Warfarin in Patients with Atrial Fibrillation (5705 citations)
- Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. (2715 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Cardiology, Surgery, Myocardial infarction and Endocrinology.
Basil S. Lewis integrates many fields in his works, including Internal medicine and In patient.
Basil S. Lewis has researched Cardiology in several fields, including Radiology and Blood pressure.
A large part of his Surgery studies is devoted to Endoscopy.
His studies link Placebo with Myocardial infarction.
His research integrates issues of Aspirin and Warfarin in his study of Stroke.
He most often published in these fields:
- Internal medicine (73.00%)
- Cardiology (52.22%)
- Surgery (16.48%)
What were the highlights of his more recent work (between 2011-2021)?
- Internal medicine (73.00%)
- Cardiology (52.22%)
- Myocardial infarction (13.69%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Cardiology, Myocardial infarction, Stroke and In patient.
His biological study spans a wide range of topics, including Placebo and Surgery.
His Cardiology study combines topics in areas such as Asymptomatic and Hazard ratio.
Basil S. Lewis combines subjects such as Diabetes mellitus, Evolocumab and PCSK9 with his study of Myocardial infarction.
In Stroke, he works on issues like Aspirin, which are connected to Rivaroxaban and Pantoprazole.
The Apixaban study combines topics in areas such as Concomitant and Vitamin K antagonist.
Between 2011 and 2021, his most popular works were:
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials (2576 citations)
- Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease (914 citations)
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASDThe Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD) (719 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Surgery
- Myocardial infarction
Basil S. Lewis mostly deals with Internal medicine, Cardiology, Myocardial infarction, Atrial fibrillation and Stroke.
His study in Internal medicine is interdisciplinary in nature, drawing from both Placebo and Surgery.
His Surgery research incorporates elements of Platelet aggregation inhibitor, Subgroup analysis and Vorapaxar.
His work on Acute coronary syndrome, Coronary artery disease and Ticagrelor as part of general Cardiology research is often related to In patient, thus linking different fields of science.
His work deals with themes such as Evolocumab, Diabetes mellitus, PCSK9, Physical therapy and Rosuvastatin, which intersect with Myocardial infarction.
His study looks at the relationship between Stroke and topics such as Aspirin, which overlap with Pantoprazole, Rivaroxaban, Embolism, Lower risk and Ischaemic stroke.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
